Investors who have suffered losses can register their claims on the relevant platform.

On June 3, 2026, Shenwu Energy Saving Co.,Ltd. (000820) announced it had received a formal investigation notice from the China Securities Regulatory Commission (CSRC). The CSRC has decided to initiate an investigation into the company due to suspected violations of information disclosure laws and regulations, in accordance with the Securities Law and the Administrative Punishment Law. Legal counsel specializing in securities claims has indicated that the investor compensation case for Shenwu Energy Saving has been preliminarily initiated, and affected investors are advised to monitor the situation.

The legal opinion is that investors who purchased Shenwu Energy Saving shares before June 3, 2026, and sold or continued to hold those shares after June 3, 2026, can now begin preparing to file claims.

Additional Legal Action

In addition to the Shenwu Energy Saving case, on June 16, 2026, a batch of investor claims against Hainan Poly Pharm.Co.,Ltd. (300630) represented by legal counsel was resubmitted for filing at the Haikou Intermediate People's Court.

Previously, a first-instance judgment in a case against Hainan Poly Pharm. represented by the same legal team resulted in a favorable ruling for the investors. The case has since seen substantive progress. The legal team is concurrently advancing the filing of subsequent cases and continues to accept mandates from other investors seeking compensation.

Background on Hainan Poly Pharm. Penalty

On March 21, 2025, Hainan Poly Pharm. announced it had received an Administrative Penalty Decision from the CSRC. The investigation found that the company had overstated its 2021 operating revenue by RMB 514,604,184.72, accounting for 34.11% of the disclosed revenue for that year, with corresponding overstated operating costs of RMB 206,585,749.23 and overstated total profit of RMB 308,018,435.49, representing 65.88% of the disclosed total profit. For 2022, the company overstated operating revenue by RMB 515,899,077.56 (28.56% of disclosed revenue), with corresponding overstated operating costs of RMB 128,481,820.04 and overstated total profit of RMB 387,417,257.52, accounting for 88.27% of the disclosed total profit. The company's 2021 and 2022 annual reports contained false records.

Based on precedent, legal counsel advises that investors who purchased Hainan Poly Pharm. shares between April 26, 2022, and April 17, 2024, and sold or continued to hold those shares after April 17, 2024, may still initiate claims for compensation.